Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Israel has been steadily growing in recent years, driven by a combination of factors such as an aging population, increased awareness of the risks associated with blood clots, and advancements in medical technology.
Customer preferences: Patients in Israel are increasingly opting for newer anti-coagulant drugs that offer greater efficacy and fewer side effects compared to traditional blood thinners. This trend is in line with global preferences, as patients seek out treatments that offer better outcomes and quality of life.
Trends in the market: One of the key trends in the Israeli Anti-Coagulants market is the growing adoption of direct oral anticoagulants (DOACs), which are more effective and easier to use than traditional warfarin. DOACs are becoming increasingly popular among patients due to their lower risk of bleeding and fewer dietary restrictions. Additionally, the market is seeing a rise in the use of combination therapies, which involve the use of multiple drugs to achieve better outcomes.
Local special circumstances: Israel has a unique healthcare system that is characterized by a high level of government involvement. The government provides universal healthcare coverage to all citizens, and this has helped to increase access to Anti-Coagulants for patients across the country. Additionally, Israel has a highly developed medical technology sector, which has contributed to the development of cutting-edge Anti-Coagulant drugs and devices.
Underlying macroeconomic factors: Israel's aging population is a key driver of growth in the Anti-Coagulants market, as older adults are at higher risk of developing blood clots. Additionally, Israel has a high prevalence of certain health conditions such as atrial fibrillation, which can increase the risk of blood clots. The country's strong economy and high levels of healthcare spending have also contributed to the growth of the Anti-Coagulants market in recent years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
